EUCTR2006-004634-32-ES进行中（未招募）不适用
Estudio de fase III randomizado, abierto del Intergroup: Efecto de la adición de bevacizumab a quimioterapia (QT) basada en fluoropirimidinas como tratamiento en segunda línea de pacientes con cáncer colorrectal metastático que han manifestado progresión de la enfermedad durante un tratamiento de combinación con QT estándar/bevacizumab en primera línea.A randomized phase III study: Effect of adding Bevacizumab to cross over fluoropyrimidine based chemotherapy (CTx) in patients with metastatic colorectal cancer and disease progression under first-line standard CTx / Bevacizumab combination - TM
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 820
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients with histological confirmed diagnosis of metastatic CRC and disease progression (according to RECIST assessed by investigator, documented by CT or MRI), previously treated with first-line Therapy (Bevacizumab and Fluoropyrimidin / Oxaliplatin based or Bevacizumab and Fluoropyrimidin/ Irinotecan based CTx) and are no candidates for primary metastectomy.
- •- Disease Progression ? 2 months after last bevacizumab administration
- •- Evaluation of tumour disease according to RECIST by investigator, 4 weeks or less prior to randomization
- •- No major surgery within 4 weeks prior to randomization. Wound healing has to be completed
- •- Age ?18 years
- •- Life expectancy > 3 month
- •- ECOG ? 2
- •- Neutrophils ? 1.500/µl
- •- Platelets ? 100.000µl
- •- Hemoglobin > 9 g/dl
- •- Creatinine clearance > 30 ml/min (Dosage modification for Capecitabine if creatinine clearance < 30-50 ml/min), serum creatinine < 1,25 x upper normal limit,
- •- Serum bilirubin < 1,25x upper normal limit, AST / ALT < 2.5 x UNL
- •- In case of liver metastasis, serum bilirubin < 1,5 x upper normal limit, AST/ALT < 5 x UNL
- •- Signed written informed consent
- •- Fertile women and men of childbearing potential (<2 years after last menstruation in women) must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •?Diagnosis of progression of disease more than 2 m after last Bevacizumab (BV) administration
- •? First Line patients who had a PFS in first-line of < 3 m
- •? Patient receiving less than 3 consecutive months of BV in first line therapy
- •? Treatment with any other investigational agent or other biological agent (e.g. cetuximab)
- •? Participation in another clinical trial within 30 d prior to entering this study
- •? Concomitant use with St John?s Wort (for capecitabine based CTx)
- •? Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg
- •? Prior history of hypertensive crisis or hypertensive encephalopathy
- •? NYHA Class II or greater CHF
- •? History of myocardial infarction or unstable angina within 6 m prior to Day 1
- •? Known CNS disease, expect for treated brain metastasis (treated brain metastases are defined as having no evidence of progression or haemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging during the screening period. Anticonvulsants are allowed. Treatment for brain metastases may include whole brain radiotherapy, radiosurgery or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 m of start of study therapy will be excluded.
- •? Significant vascular disease (e.g. aortic aneurysm requiring surgical intervention, pulmonary embolism or recent peripheral arterial thrombosis) within 6 m prior start of study treatment.
- •? History of haemoptysis (? ½ tsp of bright red blood per episode) within 1 m prior start of study treatment
- •? Evidence of bleeding diathesis or significant coagulopathy (in absence of therapeutic anticoagulation)
- •? Major surgical procedure, open biopsy, or significant traumatic injury within 28 d prior to start of study therapy, or anticipation of need for major surgical procedure during the course of the study
- •? Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 d prior start of study therapy
- •? History of abdominal fistula or gastrointestinal perforation within 6 m prior start of study therapy.
- •? Serious, non healing wound, active ulcer, or untreated bone fracture
- •? History or evidence upon physical/neurological examination of CNS disease (unrelated to cancer) (unless adequately treated with standard medical therapy) e.g. uncontrolled seizures
- •? Past or current history (within the last 2 years prior to treatment start) of other malignancies except metastatic colorectal cancer (patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible)
- •? Known hypersensitivity to any of the study drugs
- •? Acute intra abdominal inflammatory process
- •? Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications
- •? Patients with contraindication for cross over chemotherapy (e.g. patients treated with irinotecan based first line therapy and serious polyneuropathy > grade 1, not feasible for oxaliplatin based cross over second line therapy, or patients treated with oxaliplatin based first line therapy and hereditary fructose intolerance not feasible for Iri
研究者
相似试验
进行中（未招募）
1 期
Estudio de fase III, randomizado, abierto, para comparar la farmacocinética, eficacia y seguridad de trastuzumab por vía subcutánea (SC) con trastuzumab por vía intravenosa (IV) administrado a mujeres con cáncer de mama precoz (CMP) HER2 positivo.Cáncer de mama localmente avanzado, inflamatorio o en estadio inicial HER2 positivoMedDRA version: 9.1Level: LLTClassification code 10006194Term: Breast cancer NOS stage IMedDRA version: 9.1Level: LLTClassification code 10006195Term: Breast cancer NOS stage IIMedDRA version: 9.1Level: LLTClassification code 10006196Term: Breast cancer NOS stage IIIMedDRA version: 9.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2008-007326-19-ESF. Hoffmann-La Roche Ltd552
进行中（未招募）
1 期
Estudio en fase III aleatorizado y abierto para comparar GSK2118436 con DTIC en sujetos con melanoma avanzado (estadio III) o metastásico (estadio IV) y mutación de BRAF, no tratados previamente.A Phase III randomized, open-label study comparing GSK2118436 to DTIC in previously untreated subjects with BRAF mutation positive advanced (Stage III) or metastatic (Stage IV) melanoma.EUCTR2009-015298-11-ESGlaxoSmithKline, S.A.200
进行中（未招募）
不适用
?Estudio en fase 3, aleatorizado y abierto, de la eficacia y seguridad de PF-02341066 frente a quimioterapia estándar (pemetrexed o docetaxel) en pacientes con cáncer de pulmón no microcítico (NSCLC) avanzado que presentan una translocación o inversión en el locus del gen de la quinasa de linfoma anaplásico (ALK)?PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF-02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUSCANCER DE PULMON NO MICROCÍTICO (NSCLC) AVANZADO QUE PRESENTA UNA TRANSLOCACIÓN O INVERSIÓN EN EL LOCUS DEL GEN DE LA QUINASA DE LINFOMA ANAPLÁSICO (ALK)ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUSMedDRA version: 12.0Level: LLTClassification code 10061873Term: Non-small cell lung cancerEUCTR2009-012595-27-ESPfizer, S.A.318
进行中（未招募）
不适用
Estudio de fase 3, abierto y aleatorizado, de inotuzumab ozogamicina (CMC-544) administrado en combinación con rituximab, comparado con un tratamiento definido a elección del investigador, a sujetos con linfoma no Hodgkin de células B folicular, CD22 positivo, en recidiva o refractarioAn Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or Refractory, CD22- Positive, Follicular B-Cell Non Hodgkin’s LymphomaEUCTR2007-000219-27-ESWyeth Research Division of Wyeth Pharmaceuticals Inc978
进行中（未招募）
不适用
Studio Multicentrico, di Fase III, randomizzato, in doppio cieco, controllato verso trattamento attivo e verso placebo, con sospensione randomizzata del farmaco in studio, per valutare la sicurezza e l'efficacia di CG5503 RP orale in pazienti con dolore cronico da cancro di intensita' moderata-severa. - NDmoderate to severe chronic malignant tumor-related painMedDRA version: 9.1Level: LLTClassification code 10058019Term: Cancer painEUCTR2006-004997-28-ITGruenenthal GmbH573